Why healthcare stocks got a bump from Trump

Glenn Freeman  |  28/11/2016Text size  Decrease  Increase  |  

Glenn Freeman: I'm Glenn Freeman for Morningstar and I'm joined today by Chris Kallos, our Australian healthcare equities analyst.

Chris, thanks for joining us.

Chris Kallos: Thank you, Glenn.

Freeman: Just firstly Chris, Australian healthcare companies have been performing quite strongly, particularly in recent years. Why is this?

Kallos: Well, a combination of things. Firstly, on a relative basis, we've seen the mining sector fall away. Banks have been up and down.

So, healthcare has been pretty consistent.

Added to that is the fact that many of the large healthcare companies that we have around us today have been around for a number of decades during periods of volatility.

So, what we're seeing now is a seasoned performance, if you will. People have gone through rough patches who have benefited from consolidation, who have worked up very strong business models--and names that come to mind include Ramsay, Sonic, CSL.

They've been around for decades. So, it stands to reason that they've worked out certain wrinkles in their business plans and their business models and that's what we see today.

Freeman: Now, Chris, in the lead up to the U.S. election and in the immediate aftermath, the US healthcare sector has seen some pretty big movement. How has this been reflected in the Australian healthcare sector?

Kallos: Well, the healthcare sector like all the other sectors were bumped on the election of Donald Trump.

There is a high expectation that he will roll back some red tape for drug approvals in the FDA and there's also now a reality of Hillary Clinton not being able to execute or act on her promise to control drug prices.

So, both of those things have been seeing positively for the US healthcare sector and we've moved in tandem out of sympathy or sentiment.

Obviously, not every stock is affected the same way, but companies like CSL, Mayne Pharma on the generics side, theoretically could benefit from this kind of rhetoric on Donald Trump's side.

Freeman: The US government has been conducting an enquiry into generic drug pricing. How has this flowed on to Australian companies?

Kallos: That's right, Glenn. Well, that probe came directly as a result of a few scandals last year in generic pricing and allegations of gouging which fueled a lot of the rhetoric that the democrats were pushing.

The probe itself is into certain generic molecules of doxycycline and digoxin. The only companies that are affected in that space are Mayne Pharma.

However, these are very small components in their overall portfolio. I don't think it's got any bearing on their business as such going forward.

Freeman: Now, just lastly, looking ahead, where do you expect growth will come from for Australian healthcare companies?

Kallos: Given that the large caps, namely, CSL, ResMed, Ramsay and Sonic are all now global companies, I think most of the growth will come offshore. That's definitely the case with Sonic and Ramsay.

Ramsay is the number one private service provider in France, for instance. They've got a very strong business in the UK.

Sonic, likewise, is doing a lot of work in Europe and also the UK. And that makes sense given that their market share is almost kept out in the Australian domestic environment.

 

Video Archive...

Exclusive: An interview with Westpac CEO, Brian Hartzer - Part 3
20/07/2017  Insights on Australia's housing market, China's effect on domestic banks, and cyber-security readiness, in the final instalment of Brian Hartzer's interview with Morningstar's David Ellis.
Telstra won't be blown away by headwinds
17/07/2017  While it faces what Morningstar equity analyst Brian Han describes as a whirlwind of negatives, he suggests investors shouldn’t hang up on Telstra.
Exclusive: An interview with Westpac CEO, Brian Hartzer - Part 2
13/07/2017  Westpac CEO Brian Hartzer joins Morningstar banking analyst David Ellis to discuss digital disruption, regulatory change and Australian banks' social license.
The home-truths of investing
12/07/2017  Look for companies that sit outside the cycle; heed the lessons of history; and remember the power of compounding, says Bennelong's Neale Goldston-Morris.
Exclusive: An interview with Westpac CEO, Brian Hartzer - Part 1
06/07/2017  Brian Hartzer, CEO, Westpac joins Morningstar senior analyst David Ellis to discuss his role leading Australia's oldest bank, how Westpac can continue to grow value, and its commitment to sustainability.
Self-managed super is not Do-it-yourself
03/07/2017  There are a few common pitfalls in running a self-managed super fund that mean trustees shouldn't go it alone entirely, says BT Financial Group's head of financial literacy, Bryan Ashenden.
Investing to protect on the downside
30/06/2017  There are investment strategies you can adopt to mitigate volatility-linked fear and uncertainty in markets, explains Roy Maslen, chief investment officer – Australian equities, AllianceBernstein.
Don’t overdo benchmark consideration
28/06/2017  Being benchmark agnostic is the most effective approach to fixed income investing, according to Anujeet Sareen, portfolio manager, Brandywine Global.
Factor-based investing using ETFs
26/06/2017  Investors should consider style-exposures--such as value, defensive or yield-- they would like in their portfolios, explains Jonathan Shead, head of portfolio strategists – Asia Pacific, State Street Global Advisors
Volatility plays to active manager strengths
--  The climate of political volatility in the US holds important implications for investors and the funds they invest in, particularly around Donald Trump's ability to pass legislation through Congress, says Pimco's Libby Cantrill.
Is the FTSE 100 Facing Another Market Crash?
16/06/2017  Ten years on from the pre-crisis FTSE 100 high, Morningstar UK's Emma Wall examines how UK stocks have fared
How to guard against retirement threats
16/06/2017  As retirement approaches, even the best-laid plans can go awry, as Tim Steffen tells Christine Benz, Morningstar US.
PIMCO Global Credit Fund
07/06/2017  The PIMCO Global Credit strategy receives a Morningstar Analyst Rating of Silver due to its sizeable and highly capable credit research team.
PIMCO Income Fund
07/06/2017  Morningstar's Tim Wong looks at the strengths and competitive advantages of this Silver-rated strategy.
3 pockets of opportunity in fixed income
07/06/2017  The head of PIMCO Australia portfolio management explains his views on active management in fixed income and outlines where he sees most value in this space.
Trump administration biggest macro threat for investors
05/06/2017  Even as European political volatility subsides, the US Government remains a considerable threat to financial markets, says Colleen Barbeau, director of equity portfolio management, Franklin Templeton.
Antipodes Global Fund: Class P
01/06/2017  Antipodes constructs this portfolio based on three major objectives--capital preservation, inclusion of attractively priced businesses, and investment resilience.
Investors Mutual WS Future Leaders Fund
01/06/2017  Investors Mutual Future Leaders is a capable strategy focused on investing in Australian companies outside the top 50.
Why the time is right to invest in India
25/05/2017  Indian stocks rallied after the appointment of Narendra Modi as Prime Minister--but then subsequently fell. UK-based investment manager Jonathan Schiessl says now is the time to buy.
When should you pay active fund fees?
23/05/2017  When is it worth paying higher fund fees for active fund management? The single most important factor effecting a fund's relative performance is its price.